Minneapolis, MN, United States of America

Seleeke Flingai

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2018-2022

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Seleeke Flingai

Introduction

Seleeke Flingai is a notable inventor based in Minneapolis, MN, who has made significant contributions to the field of biotechnology. With a total of four patents to his name, Flingai's work focuses on the development of DNA antibody constructs and their applications in medicine. His innovative approach has the potential to revolutionize the treatment of various diseases.

Latest Patents

Flingai's latest patents include groundbreaking compositions that involve recombinant nucleic acid sequences encoding antibodies. These patents disclose methods for generating synthetic antibodies in subjects through the administration of these compositions. Furthermore, his work outlines methods for preventing and treating diseases using these innovative compositions and generation techniques.

Career Highlights

Throughout his career, Seleeke Flingai has worked with prestigious organizations such as the University of Pennsylvania and Inovio Pharmaceuticals, Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to cutting-edge research.

Collaborations

Flingai has had the opportunity to work alongside esteemed colleagues, including David B Weiner and Karuppiah Muthumani. These collaborations have further enhanced his research and development efforts in the biotechnology sector.

Conclusion

In summary, Seleeke Flingai is an accomplished inventor whose work in DNA antibody constructs holds promise for advancing medical treatments. His innovative patents and collaborations reflect his commitment to improving healthcare through scientific discovery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…